Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Significant association between ERCC2 and MTHR polymorphisms and breast cancer susceptibility in Moroccan population: genotype and haplotype analysis in a case-control study

Authors: Hanaa Hardi, Rahma Melki, Zouhour Boughaleb, Tijani El Harroudi, Souria Aissaoui, Noureddine Boukhatem

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Genetic determinants of breast cancer (BC) remained largely unknown in the majority of Moroccan patients. The purpose of this study was to explore the association of ERCC2 and MTHFR polymorphisms with genetic susceptibility to breast cancer in Moroccan population.

Methods

We genotyped ERCC2 polymorphisms (rs1799793 (G934A) and rs13181 (A2251C)) and MTHFR polymorphisms (rs1801133 (C677T) and rs1801131 (A1298C)) using TaqMan SNP Genotyping Assays. Genotypes were compared in 151 BC cases and 156 population-matched controls. Allelic, genotypic and haplotype associations with the risk and clinicopathological features of BC were assessed using logistic regression analyses.

Results

ERCC2-rs1799793-AA genotype was associated with high risk of BC compared to wild type genotype (recessive model: OR: 2.90, 95% CI: 1.34–6.26, p = 0.0069) even after Bonferroni correction (p < 0,0125). MTHFR rs1801133-TT genotype was associated with increased risk of BC (recessive model, OR: 2.49, 95% CI: 1.17–5.29, p = 0.017) but the association turned insignificant after Bonferroni correction. For the rest of SNPs, no statistical associations to BC risk were detected.
Significant association with clinical features was detected for MTHFR-rs1801133-TC genotype with early age at diagnosis and familial BC. Following Bonferroni correction, only association with familial BC remained significant. MTHFR-rs1801131-CC genotype was associated with sporadic BC. ERCC2-rs1799793-AA genotype correlated with ER+ and PR+ breast cancer. ERCC2-rs13181-CA genotype was significantly associated large tumors (T ≥ 3) in BC patients. None of these associations passed Bonferroni correction.
Haplotype analysis showed that ERCC2 A-C haplotype was significantly associated with increased BC risk (OR: 3.71, 95% CI: 1.7–8.12, p = 0.0002 and p = 0.0008 before and after Bonferroni correction, respectively) and positive expression of ER and PR in BC patients. ERCC2 G-C haplotype was correlated with PR negative and larger tumor (T4). We did not find any MTHFR haplotypes associated with BC susceptibility. However, the less common haplotype MTHFR T-C was more frequent in young patients and in familial breast cancer, while MTHFR C-C haplotype was associated with sporadic BC form.

Conclusions

Our findings are a first observation of association between ERCC2 SNPs and breast cancer in Moroccan population. The results suggested that ERCC2 and MTHFR polymorphisms may be reliable for assessing risk and prognosis of BC in Moroccan population.
Literature
1.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in (GLOBOCAN) 2012. Int J Cancer. 2015;136:E359–86.CrossRefPubMed
2.
Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3:524–48.CrossRef
3.
Chouchane L, Boussen H, Sastry KSR. Breast cancer in Arab populations: molecular characteristics and disease management implications. Lancet Oncol. 2013;14:417–24.CrossRef
4.
Fondation Lalla Salma Prévention et traitement des Cancers. Registre des cancers de la région du Grand Casablanca pour la période 2008–2012. 2016.
5.
Khalis M, Rhazi K, Charaka H, Chajès V, Rinaldi S, Nejjari C, Romieu I, Charbotel B. Female breast cancer incidence and mortality in Morocco: comparison with other countries. Asian Pac J Cancer Prev. 2016;17:5211–6.PubMedPubMedCentral
6.
Hamdi Y, Soucy P, Adoue V, Michailidou K, Canisius S, Lemaçon A, Droit A, Andrulis IL, Anton-Culver H, Arndt V, et al. Association of breast cancer risk with genetic variants showing differential allelic expression: identification of a novel breast cancer susceptibility locus at 4q21. Oncotarget. 2016;7:80140–63.CrossRefPubMedPubMedCentral
7.
Shi M, O'Brien KM, Sandler DP, Taylor JA, Zaykin DV, Weinberg CR. Previous GWAS hits in relation to young-onset breast cancer. Breast Cancer Res Treat. 2017;161:333–44.CrossRefPubMed
8.
Véron A, Blein S, Cox DG. Genome-wide association studies and the clinic: a focus on breast cancer. Biomark Med. 2014;8:287–96.CrossRefPubMed
9.
Wang T, Wang H, Guo H, Yang S, Zhu G, Guo H, et al. Polymorphisms in the DNA repair gene ERCC2/XPD and breast cancer risk: a HapMap-based case–control study among Han women in a chinese less-developed area. Genet Test Mol Biomarkers. 2014;18:703–10.CrossRefPubMedPubMedCentral
10.
Lanara Z, Giannopoulou E, Fullen M, Kostantinopoulos E, Nebel J-C, Kalofonos HP, et al. Comparative study and meta-analysis of meta-analysis studies for the correlation of genomic markers with early cancer detection. Hum Genomics. 2013;7:14.CrossRefPubMedPubMedCentral
11.
Michailidou K, Hall P, Anna GN, Ghoussaini M, Dennis J, Milne RL, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet. 2013;45:353–61.CrossRefPubMedPubMedCentral
12.
Michailidou K, Beesley J, Lindstrom S, Canisius S, Dennis J, Lush MJ, et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet. 2015;47:373–80.CrossRefPubMedPubMedCentral
13.
Jouhadi H, Tazzite A, Azeddoug H, Naim A, Nadifi S, Benider A. Clinical and pathological features of BRCA1/2 tumors in a sample of high-risk Moroccan breast cancer patients. BMC Res Notes. 2016;9:248.CrossRefPubMedPubMedCentral
14.
Laraqui A, Uhrhammer N, Idriss L-A, Rhaffouli HEL, Baghdadi J, Dehayni M, et al. Mutation screening of the BRCA1 gene in early onset and familial breast/ovarian cancer in Moroccan population. Int J Med Sci. 2013;10:60–7.CrossRefPubMed
15.
Rahoui J, Sbitti Y, Touil N, Laraqui A, Ibrahimi A, Rhrab B, et al. The single nucleotide polymorphism +936 C/T VEGF is associated with human epidermal growth factor receptor 2 expression in Moroccan breast cancer women. Med Oncol. 2014;31:336.CrossRefPubMed
16.
Marouf C, Göhler S, Filho M, Hajji O, Hemminki K, Nadifi S, et al. Analysis of functional germline variants in APOBEC3 and driver genes on breast cancer risk in Moroccan study population. BMC Cancer. 2016;16:165.CrossRefPubMedPubMedCentral
17.
Gómez-Díaz B, DE LA Luz Ayala-Madrigal M, Gutiérrez-Angulo M, Valle-Solis AE, Linares-González LM, González-Guzmán R, Cruz-Guillén D, Cedeño-Garcidueñas AL, Canto P, López-Hernández LB. Analysis of ERCC1 and ERCC2 gene variants in osteosarcoma, colorectal and breast cancer. Oncol Lett. 2015;9:1657–61.CrossRefPubMedPubMedCentral
18.
Xie SZ, Liu ZZ, Yu J, Liu L, Wang W, Xie DL, et al. Association between the MTHFR C677T polymorphism and risk of cancer: evidence from 446 case–control studies. Tumor Biol. 2015;36:8953–72.CrossRef
19.
Diakite B, Tazzite A, Hamzi K, Jouhadi H, Nadifi S. Methylenetetrahydrofolate reductase C677T polymorphism and breast cancer risk in Moroccan women. Afr Health Sci. 2012;12:204–9.PubMedPubMedCentral
20.
21.
22.
Solé X, Guinó E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinform Oxf Engl. 2006;22:1928–9.CrossRef
23.
Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263–5.CrossRefPubMed
24.
Katarzyna P-S, Scott RJ, Górski B, Cybulski C, Kurzawski G, Dymerska D, et al. Polymorphisms in nucleotide excision repair genes and susceptibility to colorectal cancer in the polish population. Mol Biol Rep. 2015;42:755–64.CrossRef
25.
Srivastava K, Srivastava A, Mittal B. Polymorphisms in ERCC2, MSH2, and OGG1 DNA repair genes and gallbladder cancer risk in a population of Northern India. Cancer. 2010;116:3160–9.CrossRefPubMed
26.
Chu H, Gu D, Xu M, Xu Z, Gong Y, Gong W, et al. A genetic variant in ERCC2 is associated with gastric cancer prognosis in a Chinese population. Mutagenesis. 2013;28:441–6.CrossRefPubMed
27.
Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomark Prev. 2002;11:1513–30.
28.
Au WW, Salama SA, Sierra-Torres CH. Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect. 2003;111:1843–50.CrossRefPubMedPubMedCentral
29.
Wolfe KJ, Wickliffe JK, Hill CE, Paolini M, Ammenheuser MM, Abdel-Rahman SZ. Single nucleotide polymorphisms of the DNA repair gene XPD/ERCC2 alter mRNA expression. Pharmacogenet Genomics. 2007;17:897–905.CrossRefPubMed
30.
Shadrina AS, Ermolenko NA, Boyarskikh UA, Sinkina TV, Lazarev AF, Petrova VD, et al. Polymorphisms in DNA repair genes and breast cancer risk in Russian population: a case-control study. Clin Exp Med. 2016;16:21–8.CrossRefPubMed
31.
Hussien YM, Gharib AF, Awad HA, Karam RA, Elsawy WH. Impact of DNA repair genes polymorphism (XPD and XRCC1) on the risk of breast cancer in Egyptian female patients. Mol Biol Rep. 2012;39:1895–901.CrossRefPubMed
32.
Wang HC, Liu CS, Wang CH, Tsai RY, Tsai CW, Wang RF, et al. Significant association of XPD Asp312Asn polymorphism with breast cancer in Taiwanese patients. Chin J Physiol. 2010;53:130–5.CrossRefPubMed
33.
Zhang L, Zhang Z, Yan W. Single nucleotide polymorphisms for DNA repair genes in breast cancer patients. Clin Chim Acta. 2005;359:150–5.CrossRefPubMed
34.
He BS, Xu T, Pan YQ, Wang HJ, Cho WC, Lin K, Sun HL, Gao TY, Wang SK. Nucleotide excision repair pathway gene polymorphisms are linked to breast cancer risk in a Chinese population. Oncotarget. 2016;7:84872–82.PubMedPubMedCentral
35.
Yan Y, Liang H, Light M, Li T, Deng Y, Li M, et al. XPD Asp312Asn and Lys751Gln polymorphisms and breast cancer susceptibility: a meta-analysis. Tumor Biol. 2014;35:1907–15.CrossRef
36.
Pabalan N, Ofelia FP, Sung L, Jarjanazi H, Ozcelik H. Meta-analysis of two ERCC2 (XPD) polymorphisms, Asp312Asn and Lys751Gln, in breast cancer. Breast Cancer Res Treat. 2010;124:531–41.CrossRefPubMed
37.
Costa S, Pinto D, Pereira D, Rodrigues H, Jorge C-T, Medeiros R, et al. DNA repair polymorphisms might contribute differentially on familial and sporadic breast cancer susceptibility: a study on a Portuguese population. Breast Cancer Res Treat. 2007;103:209–17.CrossRefPubMed
38.
Dębniak T, Scott RJ, Huzarski T, Byrski T, Masojć B, van de Wetering T, et al. XPD common variants and their association with melanoma and breast cancer risk. Breast Cancer Res Treat. 2006;98:209–15.CrossRefPubMed
39.
Kuschel B, Georgia CT, Spurdle AB, Chen X, Hopper JL, Giles GG, et al. Common polymorphisms in ERCC2 (Xeroderma pigmentosum D) are not associated with breast cancer risk. Cancer Epidemiol Biomark Prev. 2005;14:1828–31.CrossRef
40.
41.
Jiang Z, Li C, Xu Y, Cai S, Wang X. Associations between XPD polymorphisms and risk of breast cancer: a meta-analysis. Breast Cancer Res Treat. 2010;123:203–12.CrossRefPubMed
42.
Yao L, Qiu LX, Yu L, Yang Z, Yu X-J, Zhong Y, et al. The association between ERCC2 Asp312Asn polymorphism and breast cancer risk: a meta-analysis involving 22,766 subjects. Breast Cancer Res Treat. 2010;123:227–31.CrossRefPubMed
43.
44.
McCafferty MP, McNeil RE, Miller N, Kerin MJ. Interactions between the estrogen receptor, its cofactors and microRNAs in breast cancer. Breast Cancer Res Treat. 2009;116:425–32.CrossRefPubMed
45.
Coin F, Marinoni J-C, Rodolfo C, Fribourg S, Pedrini A, Egly J-M. Mutations in the XPD helicase gene result in XP and TTD phenotypes, preventing interaction between XPD and the p44 subunit of TFIIH. Nat Genet. 1998;20:184–8.CrossRefPubMed
46.
Tupikowski K, Partyka A, Kolodziej A, Dembowski J, Debinski P, Halon A, et al. CTLA-4 and CD28 genes’ polymorphisms and renal cell carcinoma susceptibility in the polish population – a prospective study. Tissue Antigens. 2015;86:353–61.CrossRefPubMed
47.
Lee WC. Searching for disease-susceptibility loci by testing for Hardy-Weinberg Disequilibrium in a Gene Bank of affected individuals. Am J Epidemiol. 2003;158:397–400.CrossRefPubMed
48.
Qiu LX, Yao L, Zhang J, Zhu XD, Zhao XM, Xue K, et al. XPD Lys751Gln polymorphism and breast cancer susceptibility: a meta-analysis involving 28,709 subjects. Breast Cancer Res Treat. 2010;124:229–35.CrossRefPubMed
49.
Mitra AK, Singh N, Garg VK, Chaturvedi R, Sharma M, Rath SR. Statistically significant association of the single nucleotide polymorphism (SNP) rs13181 (ERCC2) with predisposition to squamous cell carcinomas of the head and neck (SCCHN) and breast cancer in the north Indian population. J Exp Clin Cancer Res. 2009;28:104.CrossRefPubMedPubMedCentral
50.
Smith TR, Levine EA, Freimanis RI, Akman SA, Allen GO, Hoang KN, et al. Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk. Carcinogenesis. 2008;29:2132–8.CrossRefPubMedPubMedCentral
51.
Justenhoven C, Hamann U, Pesch B, Harth V, Rabstein S, Baisch C, Vollmert C, Illig T, Ko YD, Brüning T, et al. ERCC2 genotypes and a corresponding haplotype are linked with breast cancer risk in a German population. Cancer Epidemiol Biomark Prev. 2004;13:2059–64.
52.
Jiao L, Hassan MM, Bondy ML, Abbruzzese JL, Evans DB, Li D. The XPD Asp312Asn and Lys751Gln polymorphisms, corresponding haplotype, and pancreatic cancer risk. Cancer Lett. 2007;245:61–8.CrossRefPubMed
53.
Gonzales MC, Yu P, Shiao PSK. MTHFR gene polymorphism mutations and air pollution as risk factors for breast cancer: a metaprediction study. Nurs Res. 2017;66:152–63.CrossRefPubMedPubMedCentral
54.
Papandreou CN, Doxani C, Zdoukopoulos N, Vlachostergios PJ, Hatzidaki E, Bakalos G, et al. Evidence of association between methylenetetrahydrofolate reductase gene and susceptibility to breast cancer: a candidate gene association study in a South-Eastern European population. DNA Cell Biol. 2012;31:193–8.CrossRefPubMed
55.
Weisberg IS, Jacques PF, Selhub J, Bostom AG, Chen Z, Ellison CR, et al. The (1298A→C) polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. Atherosclerosis. 2001;156:409–15.CrossRefPubMed
56.
Yamada K, Chen Z, Rozen R, Matthews RG. Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase. Proc Natl Acad Sci. 2001;98:14853–8.CrossRefPubMedPubMedCentral
57.
He L, Shen Y. MTHFR C677T polymorphism and breast, ovarian cancer risk: a meta-analysis of 19,260 patients and 26,364 controls. Onco Targets Ther. 2017;10:227–38.CrossRefPubMedPubMedCentral
58.
Naushad S, Divya C, Ramaiah JM, Hussain T, Alrokayan SA, Kutala V. Population-level diversity in the association of genetic polymorphisms of one-carbon metabolism with breast cancer risk. J Community Genet. 2016;7:279–90.CrossRefPubMedPubMedCentral
59.
Waseem M, Hussain SR, Kumar S, Serajuddin M, Mahdi F, Sonkar SK, Bansal C, Ahmad MK. Association of MTHFR (C677T) gene polymorphism with breast cancer in North India. Biomark Cancer. 2016;8:111–7.CrossRefPubMedPubMedCentral
60.
Lu Q, Jiang K, Li Q, Ji YJ, Chen WL, Xue XH. Polymorphisms in the MTHFR gene are associated with breast cancer risk and prognosis in a Chinese population. Tumor Biol. 2015;36:3757–62.CrossRef
61.
Qi X, Ma X, Yang X, Fan L, Zhang Y, Zhang F, et al. Methylenetetrahydrofolate reductase polymorphisms and breast cancer risk: a meta-analysis from 41 studies with 16,480 cases and 22,388 controls. Breast Cancer Res Treat. 2010;123:499–6.CrossRefPubMed
62.
Kaya EF, Karakus N, Ulusoy AN, Özaslan C, Kara N. Association of the MTHFR gene (C677T) polymorphism with breast cancer in a Turkish population. Oncol Res Treat. 2016;39:534–8.CrossRefPubMed
63.
Song A, Zhao L, Li Y, Wu L, Li Y, Liu X, et al. Haplotypes of the MTHFR gene are associated with an increased risk of breast cancer in a Han Chinese population in Gansu province. IUBMB Life. 2016;68:526–34.CrossRefPubMed
64.
Kakkoura MG, Demetriou CA, Loizidou MA, Loucaides G, Neophytou I, Marcou Y, et al. Single-nucleotide polymorphisms in one-carbon metabolism genes, Mediterranean diet and breast cancer risk: a case–control study in the Greek-Cypriot female population. Genes Nutr. 2015;10:5.CrossRefPubMedCentral
65.
Qiu LX, Zhang J, Li WH, Zhang QL, Yu H, Wang BY, et al. Lack of association between methylenetetrahydrofolate reductase gene A1298C polymorphism and breast cancer susceptibility. Mol Biol Rep. 2011;38:2295–9.CrossRefPubMed
66.
Ziva Cerne J, Stegel V, Gersak K, Novakovic S. Lack of association between methylenetetrahydrofolate reductase genetic polymorphisms and postmenopausal breast cancer risk. Mol Med Rep. 2011;4:175–9.PubMed
67.
Justenhoven C, Hamann U, Pierl CB, Rabstein S, Pesch B, Harth V, et al. One-carbon metabolism and breast cancer risk: no association of MTHFR, MTR, and TYMS polymorphisms in the GENICA study from Germany. Cancer Epidemiol Prev Biomarkers. 2005;14:3015–8.CrossRef
68.
Langsenlehner U, Krippl P, Renner W, Babak Y-B, Wolf G, Wascher TC, et al. The common 677C>T gene polymorphism of methylenetetrahydrofolate reductase gene is not associated with breast cancer risk. Breast Cancer Res Treat. 2003;81:169–72.CrossRefPubMed
69.
Campbell IG, Baxter SW, Eccles DM, Choong DYH. Methylenetetrahydrofolate reductase polymorphism and susceptibility to breast cancer. Breast Cancer Res. 2002;4:R14.CrossRefPubMedPubMedCentral
70.
Semenza JC, Delfino RJ, Ziogas A, Hoda AC. Breast cancer risk and methylenetetrahydrofolate reductase polymorphism. Breast Cancer Res Treat. 2003;77:217–23.CrossRefPubMed
71.
Kotsopoulos J, Zhang WW, Zhang S, David M, Trudeau M, Zhang P, et al. Polymorphisms in folate metabolizing enzymes and transport proteins and the risk of breast cancer. Breast Cancer Res Treat. 2008;112:585–93.CrossRefPubMed
72.
Kaabi B, Belaaloui G, Benbrahim W, Hamizi K, Sadelaoud M, Toumi W, et al. ADRA2A germline gene polymorphism is associated to the severity, but not to the risk of breast cancer. Pathol Oncol Res. 2016;22:357–65.CrossRefPubMed
73.
Gershoni-Baruch R, Dagan E, Israeli D, Kasinetz L, Kadouri E, Friedman E. Association of the C677T polymorphism in the MTHFR gene with breast and/or ovarian cancer risk in Jewish women. Eur J Cancer. 2000;36:2313–6.CrossRefPubMed
74.
Pepe C, Guidugli L, Sensi E, Aretini P, D'Andrea E, Montagna M, et al. Methyl group metabolism gene polymorphisms as modifier of breast cancer risk in Italian BRCA1/2 carriers. Breast Cancer Res Treat. 2007;103:29–36.CrossRefPubMed
75.
Huang MY, Wang YH, Chen FM, Lee SC, Fang WY, Cheng TL, et al. Multiple genetic polymorphisms of GSTP1313AG, MDR1 3435CC, and MTHFR 677CC highly correlated with early relapse of breast cancer patients in Taiwan. Ann Surg Oncol. 2007;15:872–80.CrossRefPubMed
76.
Ergul E, Sazci A, Utkan Z, Canturk NZ. Polymorphisms in the MTHFR gene are associated with breast cancer. Tumor Biol. 2004;24:286–90.CrossRef
77.
Guillem VM, Collado M, Terol MJ, Calasanz MJ, Esteve J, Gonzalez M, et al. Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies. Leukemia. 2007;21:1413–22.CrossRefPubMed
78.
Shi M, Caprau D, Romitti P, Christensen K, Murray JC. Genotype frequencies and linkage disequilibrium in the CEPH human diversity panel for variants in folate pathway genes MTHFR, MTHFD, MTRR, RFC1, and GCP2. Birth Defects Res Part Clin Mol Teratol. 2003;67:545–9.CrossRef
79.
Awwad N, Yousef AM, Abuhaliema A, Abdalla I, Yousef M. Relationship between genetic polymorphisms in MTHFR (C677T, A1298C and their haplotypes) and the incidence of breast cancer among Jordanian females - case-control study. Asian Pac J Cancer P. 2015;16:5007–11.CrossRef
80.
Zhong S, Chen Z, Yu X, Li W, Tang J, Zhao J. A meta-analysis of genotypes and haplotypes of methylenetetrahydrofolate reductase gene polymorphisms in breast cancer. Mol Biol Rep. 2014;41:5775–85.CrossRefPubMed
81.
Fan S, Yang B, Zhi X, Wang Y, Zheng Q, Sun G. Combined genotype and haplotype distributions of MTHFR C677T and A1298C polymorphisms: a cross-sectional descriptive study of 13,473 Chinese adult women. Medicine (Baltimore). 2016;95:1–6.CrossRef
82.
Huang T, Tucker KL, Lee YC, Crott JW, Parnell LD, Shen J, et al. Methylenetetrahydrofolate reductase variants associated with hypertension and cardiovascular disease interact with dietary polyunsaturated fatty acids to modulate plasma homocysteine in Puerto Rican adults. J Nutr. 2011;141:654–9.CrossRefPubMedPubMedCentral
83.
Trifonova EA, Spiridonova MG, Gabidulina TV, Urnov FD, Puzyrev VP, Stepanov VA. Analysis of the MTHFR gene linkage disequilibrium structure and association of polymorphic gene variants with coronary atherosclerosis. Russ J Genet. 2012;48:1035–47.CrossRef
Metadata
Title
Significant association between ERCC2 and MTHR polymorphisms and breast cancer susceptibility in Moroccan population: genotype and haplotype analysis in a case-control study
Authors
Hanaa Hardi
Rahma Melki
Zouhour Boughaleb
Tijani El Harroudi
Souria Aissaoui
Noureddine Boukhatem
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4214-z

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Research article

Docetaxel facilitates lymphatic-tumor crosstalk to promote lymphangiogenesis and cancer progression

Research article

Resveratrol induces autophagy-dependent apoptosis in HL-60 cells

Study protocol

BioPro-RCMI-1505 trial: multicenter study evaluating the use of a biodegradable balloon for the treatment of intermediate risk prostate cancer by intensity modulated radiotherapy; study protocol

Case report

Esophageal cancer with severe funnel chest treated by simultaneous funnel chest surgery and thoracoscopic esophagectomy: a case report

Research article

Enhanced antitumor and anti-angiogenic effects of metronomic Vinorelbine combined with Endostar on Lewis lung carcinoma

Research article

Oral cancer incidence in Shanghai ---- a temporal trend analysis from 2003 to 2012
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits